Skip to main
EXAS
EXAS logo

Exact Sciences (EXAS) Stock Forecast & Price Target

Exact Sciences (EXAS) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 28%
Hold 39%
Sell 0%
Strong Sell 0%

Bulls say

Exact Sciences is positioned for significant growth, particularly with its Cologuard screening test, which is expected to expand its market share from approximately 15% currently to over 40%, indicating strong adoption potential. The company's recent performance has been bolstered by a remarkable 22% year-over-year growth in its core screening business, alongside positive momentum from innovative products like Cancerguard, anticipated to enhance marketing efforts and revenue generation in the near term. Furthermore, the increase in pricing for Cologuard Plus, reaching approximately $592 per test, coupled with strategic initiatives aimed at increasing screening volume to 30 million people by 2027, underscores a robust financial outlook for Exact Sciences.

Bears say

The financial outlook for Exact Sciences, as indicated, is negatively impacted by several fundamental metrics. The company has faced persistent net losses, raising concerns about its ability to achieve and maintain GAAP profitability. Additionally, Cologuard's demand sensitivity to marketing expenditures and subdued revenue projections, estimated at $4.0 billion for 2027, illustrate potential challenges in meeting growth expectations amidst an uncertain market environment.

Exact Sciences (EXAS) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 28% recommend Buy, 39% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exact Sciences (EXAS) Forecast

Analysts have given Exact Sciences (EXAS) a Buy based on their latest research and market trends.

According to 18 analysts, Exact Sciences (EXAS) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $81.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $81.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exact Sciences (EXAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.